Alnylam Announces New RNAi Therapeutic Program for the Treatment of Hepatitis B Virus (HBV) Infection and Reports an Up to 2.3 Log10 Reduction of HBV Surface Antigen (HBsAg) in Chronically Infected Chimpanzees
[Business Wire] – Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, announced today that it has named a new program to its pipeline: ALN-HBV for the treatment of hepatitis B virus infection. more
View todays social media effects on ALNY
View the latest stocks trending across Twitter. Click to view dashboard